Overview

A class action lawsuit has been filed against Indivior PLC (“Indivior” or the “Company”) (NASDAQ: INDV) and certain of the Company’s former and current senior executive officers alleging violations of the federal securities laws.  The Indivior class action lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired Indivior securities between February 22, 2024, and July 8, 2024, both dates inclusive (the “Class Period”).  Investors have until October 1, 2024, to seek appointment as lead plaintiff of the Indivior class action lawsuit.

Indivior is a global pharmaceutical company that develops, manufactures, and markets drugs to treat opioid use disorders (“OUD”) and serious mental illnesses.  Indivior’s flagship drug is SUBLOCADE, a monthly injection used to treat moderate to severe OUD.  In 2023, sales of SUBLOCADE generated net revenue of $630 million, which accounted for 58% of Indivior’s net revenue in 2023.  Indivior also sells PERSERIS, which is an injection to treat schizophrenia in U.S. adults.  In 2023, PERSERIS sales generated net revenue of $42 million.  In October 2023, Indivior launched OPVEE, a nasal spray to reverse opioid overdoses on an emergency basis.

The Indivior class actions lawsuit alleges that Defendants, throughout the Class Period, made materially false and misleading statements regarding the Company’s business, operations, and prospects.  Specifically, Defendants (1) grossly overstated their ability to forecast the negative impact of certain legislation on the financial prospects of Indivior products, which forecasting ability was far less capable and effective than Defendants had led investors and analysts to believe; (2) overstated the financial prospects of SUBLOCADE, PERSERIS, and OPVEE, and thus overstated the Company’s anticipated revenue and other financial metrics; (3) knew or recklessly disregarded that because of the negative impact of certain legislation on the financial prospects of Indivior’s products, Indivior was unlikely to meet its own previously issued and repeatedly reaffirmed fiscal year 2024 net revenue guidance, including its fiscal year 2024 net revenue guidance for SUBLOCADE, PERSERIS, and OPVEE; (4) knew or recklessly disregarded that Indivior was at a significant risk of ceasing, and/or was likely to cease, all sales and marketing activities related to PERSERIS; and (5) knew or recklessly disregarded that, as a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.

*          *          *

If you purchased or otherwise acquired Indivior securities between February 22, 2024, and July 8, 2024, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as a lead plaintiff in the Indivior class action lawsuit is October 1, 2024.